Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
J Pharm Pharm Sci. 2023 Nov 7;26:11808. doi: 10.3389/jpps.2023.11808. eCollection 2023.ABSTRACTLong-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposin...
Source: J Pharm Pharm Sci - November 29, 2023 Category: Drugs & Pharmacology Authors: Omima S Mohammed Hany G Attia Bassim M S A Mohamed Marawan A Elbaset Hany M Fayed Source Type: research
Traditional Chinese medicine for treating aplastic anemia
This article reviews the potential mechanism of traditional Chinese medicine or its active ingredients in the treatment of AA. These include improving the bone marrow microenvironment, regulating immunity, and affecting the fate of hematopoietic stem cells. This provides useful information for further treatment of AA with integration of traditional Chinese and Western medicine and the development of new treatment strategies.PMID:38022904 | PMC:PMC10679336 | DOI:10.3389/jpps.2023.11863 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - November 29, 2023 Category: Drugs & Pharmacology Authors: Jing Guan YiHui Zhao Ting Wang Rong Fu Source Type: research
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
J Pharm Pharm Sci. 2023 Nov 7;26:11808. doi: 10.3389/jpps.2023.11808. eCollection 2023.ABSTRACTLong-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposin...
Source: J Pharm Pharm Sci - November 29, 2023 Category: Drugs & Pharmacology Authors: Omima S Mohammed Hany G Attia Bassim M S A Mohamed Marawan A Elbaset Hany M Fayed Source Type: research
Traditional Chinese medicine for treating aplastic anemia
This article reviews the potential mechanism of traditional Chinese medicine or its active ingredients in the treatment of AA. These include improving the bone marrow microenvironment, regulating immunity, and affecting the fate of hematopoietic stem cells. This provides useful information for further treatment of AA with integration of traditional Chinese and Western medicine and the development of new treatment strategies.PMID:38022904 | PMC:PMC10679336 | DOI:10.3389/jpps.2023.11863 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - November 29, 2023 Category: Drugs & Pharmacology Authors: Jing Guan YiHui Zhao Ting Wang Rong Fu Source Type: research
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
J Pharm Pharm Sci. 2023 Nov 7;26:11808. doi: 10.3389/jpps.2023.11808. eCollection 2023.ABSTRACTLong-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposin...
Source: J Pharm Pharm Sci - November 29, 2023 Category: Drugs & Pharmacology Authors: Omima S Mohammed Hany G Attia Bassim M S A Mohamed Marawan A Elbaset Hany M Fayed Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
